Developing Medicines to Treat Respiratory Viruses
Altesa is a clinical-stage pharmaceutical company dedicated to developing new treatments for age-old threats to human health: high-consequence viral infections. These infections are particularly severe in vulnerable people, including those with chronic health conditions, like lung diseases, as well as the elderly and many people in underserved communities. Altesa builds upon a proven, highly successful drug development approach that has already prevented countless deaths from the two most impactful pandemics of the past 100 years—HIV/AIDS and COVID-19.
Our objective is to develop safe and effective antiviral medicines in simple oral dosage forms that, when prescribed for the right people at the right time, will halt the progression of infection before it becomes serious—or even prevent the infection altogether. This strategy extends the proven benefits of testing for viruses such as the flu or COVID-19, which have both caused suffering and death among vulnerable people but can be treated if properly diagnosed. Viral pathogens like these and others have plagued mankind for many thousands of years, but testing for and treating them is an effective strategy to blunt their impact and, ideally, to defeat them.
Making the Future Safe from Common Viral Threats
My number one priority is to make a difference in patients’ lives. I am confident that we can develop safe and highly effective treatments against a broad variety of pathogenic viruses, just as we have already done for HIV/AIDS and COVID-19.
George Painter, PhD
Co-Founder, Altesa BioSciences